iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
iTeos Therapeutics (Nasdaq: ITOS) announces that Dr. Michel Detheux, CEO, will speak at the Piper Sandler 34th Annual Healthcare Conference in New York City on November 29, 2022, at 4:30 p.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. iTeos specializes in immuno-oncology therapeutics, with programs like EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist, currently advancing in clinical trials.
- None.
- None.
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Piper Sandler 34th Annual Healthcare Conference in New York City on Tuesday, November 29, 2022 at 4:30 p.m. ET.
A live webcast of the event will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
What event will iTeos Therapeutics participate in on November 29, 2022?
Who will represent iTeos Therapeutics at the Piper Sandler conference?
What is the time and date for iTeos Therapeutics' presentation at the conference?
Where can I watch iTeos Therapeutics' presentation live?
How long will the archived replay of the iTeos Therapeutics presentation be available?
What are the main focus areas of iTeos Therapeutics?
What are the key products mentioned in the iTeos Therapeutics press release?
